Comparative Pharmacology
Head-to-head clinical analysis: ARIDOL versus PEPTAVLON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARIDOL versus PEPTAVLON.
ARIDOL vs PEPTAVLON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aridol (mannitol) is an osmotic agent that, when inhaled, increases airway osmolarity, leading to release of mediators from mast cells and eosinophils, causing bronchoconstriction in susceptible individuals. It is used as a bronchial challenge test to assess airway hyperresponsiveness.
Peptavlon is a synthetic analogue of human parathyroid hormone (PTH 1-34) that acts as a diagnostic agent by stimulating osteoblast activity and increasing serum calcium levels through PTH receptor activation.
For bronchial challenge testing: inhaled dose of 5 mg (one vial) via nebulizer, single administration.
Intravenous: 0.5 mg/kg every 6 hours; maximum single dose 40 mg.
None Documented
None Documented
16.1 ± 8.5 minutes in healthy adults. Clinical context: Short half-life allows repeated provocative testing within 2–3 hours.
Terminal elimination half-life: 8 hours (range 6-10 hours) in adults; prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min)
Primarily renal excretion of unchanged mannitol. Approximately 80% of the administered dose is excreted unchanged in urine within 12 hours; minor biliary/fecal elimination (<5%).
Renal: 65% (unchanged), Biliary: 25% (metabolites), Fecal: 10%
Category C
Category C
Diagnostic Agent
Diagnostic Agent